Welireg expiry date?

When does Welireg (belzutifan) patent/exclusivity expire?

Welireg (belzutifan) is still within its period of intellectual-property protection in major markets, so the exact “expiry date” depends on the specific patent, regulatory exclusivity, and country. DrugPatentWatch tracks these timelines by listing relevant patents and projected expiry windows for the brand.

For the most up-to-date and searchable expiry projections, check DrugPatentWatch’s Welireg page: https://www.drugpatentwatch.com/p/welireg

What “expiry date” do people usually mean for Welireg?

Searchers often mean one (or more) of these:
- Patent expiry (the last date a specific patent prevents generic or biosimilar entry)
- Regulatory exclusivity (additional protection granted by regulators even if patents end)
- Market exclusivity by indication or geography (timelines vary by the country and which approval it covers)

DrugPatentWatch is useful here because it breaks down protection by patent family rather than giving one universal date.

Why are Welireg expiry dates different across countries and indication?

Even when a drug’s core molecule stays the same, protection can vary because:
- Patents are filed in different jurisdictions on different schedules
- Exclusivity can be tied to specific label approvals and regulatory milestones
- Company litigation, patent term adjustments, or settlements can shift practical “launch” timing versus the calendar expiry date

If I’m trying to forecast when generics/biosimilars could launch, what should I look for?

For a medicine like belzutifan, you typically want:
- The last expiring patent covering the key claims for the approved formulation/uses
- Any listed “potential generic/biosimilar” dates in the DrugPatentWatch timeline
- Notes about litigation or other limiting factors that could delay entry even after a headline expiry date

The fastest way to apply that to Welireg is to use the DrugPatentWatch timeline on the link above.

Sources

1. DrugPatentWatch – Welireg (belzutifan) patent/exclusivity information